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ABSTRACT
In contrast to conventional dual-energy X-ray absorptiometry, quantitative computed tomography separately measures trabecular and
cortical volumetric bone mineral density (vBMD). Little is known about the genetic variants associated with trabecular and cortical vBMD
in humans, although both may be important for determining bone strength and osteoporotic risk. In the current analysis, we tested the
hypothesis that there are genetic variants associated with trabecular and cortical vBMD at the femoral neck by genotyping 4608 tagging
andpotentiallyfunctionalsingle-nucleotidepolymorphisms(SNPs)in383bonemetabolismcandidategenesin822Caucasianmenaged
65 years or older from the Osteoporotic Fractures in Men Study (MrOS). Promising SNP associations then weretested for replication in an
additional1155menfromthesamestudy.WeidentifiedSNPsinfivegenes(IFNAR2,NFATC1,SMAD1,HOXA,andKLF10)thatwererobustly
associated with cortical vBMD and SNPs in nine genes (APC, ATF2, BMP3, BMP7, FGF18, FLT1, TGFB3, THRB, and RUNX1) that were robustly
associated with trabecular vBMD. There was no overlap between genes associated with cortical vBMD and trabecular vBMD. These
findingsidentifynovelgeneticvariantsforcorticalandtrabecularvBMDandraisethepossibilitythatsomegeneticlocimaybeuniquefor
each bone compartment.  2010 American Society for Bone and Mineral Research.
KEY WORDS: OSTEOPOROSIS; GENETICS; BMD; MEN; QCT
Introduction
B
one mineral density (BMD) is an established determinant of
bone strength and osteoporotic fracture risk. BMD assessed
by conventional dual-energy X-ray absorptiometry (DXA)
measures the total bone mineral content in a projected area
(integral areal BMD) and cannot directly measure other skeletal
features that also may contribute to bone strength, such as the
relative amounts of cortical and trabecular bone. In contrast,
quantitative computed tomography (QCT) provides a direct
measure of cortical and trabecular volumetric BMD, both of
which may contribute to bone strength and fracture risk.
(1,2)
BMD is a highly heritable trait that is under context-specific
genetic regulation.
(3) For example, the individual genetic factors
contributing to BMD variation may differ between women and
men, between skeletal sites, and between trabecular and cortical
bone.
(4–11) Volumetric BMD (vBMD) for both compartments is
heritable, with heritability estimates of 17% to 42% for cortical
vBMD and 59% to 73% for trabecular vBMD.
(9–11) However, the
vast majority of studies in humans have searched for genetic
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330variants associated with DXA measures of integral BMD, and
most have focused on women. To better understand the genetic
determinants of compartment-specific vBMD in humans, we
explored the association of common genetic variation in 383
candidate genes with cortical and trabecular vBMD of the
femoral neck in 1977 men from the Osteoporotic Fractures in
Men Study (MrOS).
Methods
Genotyping sample
This study used a two-stage genotyping design with two
independent samples of older Caucasian men from the MrOS.
The parent study has been described, but in brief, MrOS is a
prospective cohort study of skeletal health in 5995 community-
dwelling men age 65 and older.
(12,13) Men were recruited at six
clinical centers across the United States. At the time of entry into
the study, the men were ambulatory and had at least one native
hip.
The genotyping samples were comprised of Caucasian men
who had vBMD measurements at the femoral neck and did not
report taking bone-altering medications (e.g., androgens,
antiandrogens, or oral corticosteroids) or osteoporosis treat-
ment. We used an internal replication study design by dividing
our sample in two parts and conducting our genotyping in two
phases. The first phase of genotyping was completed on a
discovery sample that included 822 men who were selected
without regard to their BMD level from the Minneapolis and
Pittsburgh clinic sites. Promising single-nucleotide polymorph-
ism (SNP) associations identified in the discovery sample then
were tested for replication in a validation sample consisting of
1156 additional men from the four other MrOS clinic sites
(Birmingham, Palo Alto, Portland, and San Diego).
Participant characteristics
Clinic staff documented participant characteristics, including age
and medical history. Participants were asked to bring all
medications used in the past 30 days to their clinic visit, where
clinic staff recorded medication use information in an electronic
database (UCSF Coordinating Center, San Francisco, CA, USA).
Height was measured by Harpenden stadiometer, and weight
was measured by balance-beam scale or digital scale with
participants wearing light clothing and no shoes.
Volumetric BMD
vBMDofthefemoralneckwasmeasuredusingQCT.Thefirst65%
of the MrOS cohort (and all ethnic minorities, regardless of when
they entered the study) were referred for QCT scans. Men having
hadahipreplacementwerenoteligibleforahipscan.Thosewho
received a QCT scan were similar to those who did not.
(14)
TomeasurevBMDatthefemoralneck,aQCTscanofthepelvic
region (from the femoral head to 3.5cm below the lesser
trochanter) was acquired at settings of 80kVp, 280mA, 3-mm
slice thickness, and 512 512 matrices. Images were acquired
using a GE Prospeed (Birmingham), GE Hispeed Advantage
(Minneapolis),PhilipsMX-8000(PaloAlto),SiemensSomatomþ4
(Pittsburgh), Philips CT-Twin (Portland), Toshiba Acquilion
(Portland) site, or Picker PQ-5000 scanner (San Diego).
Differences between the clinic sites exist, and clinic site is
included as a covariate in all models.
Each participant scan included a calibration standard of three
hydroxyapatite concentrations (150, 75, and 0mg/cm
3). Images
were converted from the native scanner Hounsfield units (HU) to
equivalent concentration (g/cm
3) of calcium hydroxyapatite
contained in the calibration standard. Regions of interest (ROI) in
the left proximal femur were identified in QCT images re-
formatted along the neutral axis of the femoral neck. The
periosteal boundary of the femur was determined with a
threshold-based region-growing algorithm. Using this boundary,
the cross-sectional area in each slice along the neutral axis of the
femoral neck between the proximal femoral neck and the lateral
edge of the trochanter was calculated, and the minimum and
maximum areas were determined. The femoral neck ROI was
defined as the portion of the neck extending from the slice with
minimum cross-sectional area (medial boundary) to a point 25%
of the distance toward the maximal cross-sectional area. Integral
volume of the ROI was computed as the total volume within the
periosteal boundary. A trabecular volume of the ROI was
obtained by applying an erosion process to the integral volume
to retain the same shape in a region fully contained within the
medullary space. The cortical volume then was defined by
applying a threshold of 0.35g/cm
3 to all voxels between the
periosteal boundary and the outer boundary of the trabecular
volume. All QCT scans were transferred to the University of
California–San Francisco for processing and central review.
Volumetric BMD for trabecular and cortical compartments was
computed over all voxels inthe respective volumes. In a group of
postmenopausal women, coefficients of variation ranged from
0.6% to 3% for vBMD measures.
(15)
Candidate gene and SNP selection
Candidate genes for vBMD were identified using evidence from
several sources, including literature searches (PubMed,
www.ncbi.nlm.nih.gov/sites/entrez?db¼PubMed), evidence of
gene expression in a normal human trabecular bone cells
(Skeletal Gene Database, sgd.nia.nih.gov [no longer available],
and NCBI UniGene, www.ncbi.nlm.nih.gov/sites/entrez?db¼
unigene), genes with functions of interest such as ‘‘regulation
of bone mineralization’’ or ‘‘skeletal development’’ (Entrez Gene,
www.ncbi.nlm.nih.gov/sites/entrez?db¼gene, and Amigo, ami-
go.geneontology.org/cgi-bin/amigo/go.cgi), genes with a skele-
tal phenotype in mice (Jackson Laboratory Mouse Genome,
www.informatics.jax.org), and genes implicated in human
skeletal disorders (Online Mendelian Inheritance in Man,
www.ncbi.nlm.nih.gov/omim). From these resources, 383 candi-
date genes were identified for genotyping.
Forthefirstphaseofgenotyping(discoverysample),publically
available data were interrogated for SNP variation in the region
surrounding the candidate gene. This was accomplished by first
creating a reference SNP panel of variants with a minor allele
frequency (MAF) of at least 5% in the genomic region spanning
30kb upstream of the transcription start site and 10kb
downstream of the candidate gene transcript. SNPs were
selected using phase I of the International HapMap Project
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discovery SNP selection.
(16) Tag SNPs were selected from this
reference SNP panel using a pairwise correlation method
(r
2 0.80).
(17) Candidate genes located near each other on the
chromosome were tagged as a unit spanning all loci of interest
(such as IGFBP2 and IGFBP5, which are located only 7.6kb from
each other on chromosome 2). In addition to tag SNPs,
potentially functional SNPs (nonsynonymous coding variants,
SNPs predicted to alter a transcription factor binding site and
putative exon splice enhancers) with MAF   1% were selected
for genotyping. These putative functional SNPs were selected
using either PupaSNP (pupasuite.bioinfo.cipf.es/) or Promolign
(polly.wustl.edu/promolign/main.html).
(18,19)
In the second phase of the project (the validation sample),
promising SNP associations from the discovery sample were
replicated. We arbitrarily defined our candidate genes as
potentially interesting for follow-up if they contained at least
oneSNPwithap valueof.015orless inthe discoverysample. We
identified 72 candidate genes for cortical vBMD and 75 for
trabecular vBMD and genotyped any SNP with a p value of .05 or
less within those genes in the validation sample. This two-tiered
strategy for selecting SNPs for follow-up was done to more
comprehensively interrogate promising candidate genes in the
validation sample than only replicating findings with a discovery
p value of .015 or less.
Genotyping
Genomic DNA was extracted from frozen whole blood speci-
mens using the Flexigene protocol (Qiagen, Valencia, CA, USA).
Genotyping in the discovery sample and most of the genotyping
in the validation sample were completed using the Illumina
Golden Gate custom assay. Blind duplicate samples and internal
controls were included to ensure reproducibility. For the
discovery sample, we observed 100% reproducibility among
the four internal controls run on each plate and 99.9%
reproducibility among the 37 duplicate participant samples. In
thevalidationsample,weobserved99.9% reproducibilityamong
the four internal controls run on each plate and 99.9%
reproducibility among the 26 blind duplicate samples. To ensure
maximum genotyping completeness in the validation sample,
loci of interest that could not be genotyped successfully using
theIlluminaGoldenGateassayweregenotypedusingoneoftwo
platforms: the TaqMan allelic discrimination assay system
(Applied Biosystems, Foster City, CA, USA) on a 7900HT Real-
time PCR instrument with probes and reagents purchased from
Applied Biosystems or the Sequenom MassARRAY iPLEX Gold
technology instrument (Sequenom, Inc., San Diego, CA, USA)
with PCR primers purchased from Invitrogen (Carlsbad, CA, USA).
Participant samples were run in duplicate for these platforms,
andanaveragereproducibility of99.8%and99.9%wasobserved
for TaqMan and Sequenom instruments, respectively.
Several participants’ samples were excluded from these
analyses because they had a low genotyping call rate (excluded
if less than 85% of SNPs called per participant, N¼14) or were
highly correlated with another sample indicating relatedness
(N¼13). Related individuals were identified by looking at
pairwise identity-by-state (IBS) distances and identifying pairs
with higher than expected IBS. Relatedness of these outlier pairs
was confirmed with clinic staff. Before analysis of the discovery
sample, 500 loci were dropped based on predefined quality
control parameters. Specifically, loci in the discovery sample that
had an observed minor allele frequency of less than 1%
(N¼129), that did not conform to the expectations of Hardy-
Weinberg equilibrium (P<.005, N¼123), or that had a low call
rate (>85% of samples missing per SNP, N¼248) were excluded
from statistical analysis.
We genotyped, on average, 1 SNP per 13 kilobase pairs (kbp)
across each candidate gene region (range: 1SNP/3 kbp – 1SNP/
97 kbp). The 4108 of 4608 SNPs genotyped successfully tagged,
on average, 64% of the SNPs with an MAF>5% in phase II of
HapMap(range pergene:1%to100%).Ofthe HapMap reference
SNPs captured by our tag SNP set, the average correlation with
the selected tag SNP was 0.97.
Statistical analysis
Uncorrelated SNPs (r
2<0.04) were selected by using a pairwise
correlation method for the discovery, validation, and pooled
samples, and these uncorrelated SNPs were used in subsequent
analysis of population stratification.
(17) Population stratification
was assessed initially using Structure.
(20) There was little
evidence of population stratification, but we accounted for
potential fine-scale population stratification in subsequent
analyses using a principal-components method.
(21) The first
principal component explained less than 0.5% variation for
cortical or trabecular vBMD in either the discovery or validation
sample.
Genetic analyses assumed an additive and recessive model.
Linear regression was used to test for an additive association
between the number of copies of the minor allele and vBMD.
Regression methods were implemented for the recessive model
to test if individuals with two copies of the minor allele differed
from those with the other genotypes. For instance, where a SNP
had fewer than 10 individuals with the rare genotype, only the
additive model was tested to minimize spurious findings based
on small genotype-specific sample sizes. Analyses were adjusted
for patient age, clinic site, and the first principal component from
the population-stratification analysis. SNPs significantly asso-
ciated inboth the discovery and validation samples (p<.05) and
having an association in the same direction for both genotyping
samples (a positive or negative regression coefficient for both
samples), regardless of the genetic model, were considered
replicated findings. Replicated SNP associations were examined
further in the pooled sample of 1977 individuals from the
discovery and validation samples. Linear regression was used in
the pooled sample to test for both additive and recessive
models. The pooled sample was adjusted for participant age,
clinicsite,andthefirstprincipalcomponentfromthepopulation-
stratification analysis. Additional adjustment for height and
weight was conducted in the pooled sample to determine if
body size attenuated the relationship between genotype and
vBMD. Linear regression analysis was used to determine the
amount of phenotypic variation explained by the significant
replicated SNPs. Correlation between individual SNPs in the
model(r
2)wasassessedtominimizecollinearityinthemodel.For
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SNP with the most missing genotypes was dropped from the
regression modeling.
Results
The average age of the 822 men in the discovery sample was 73
years (range 65 to 100 years) and did not differ from the
validation sample (Table 1). Participants in the validation sample
were slightly taller, weighed less, had a lower body mass index
(BMI), and had lower cortical and trabecular vBMD at the femoral
neck (p<.001 for all).
Of the 4108 SNPs genotyped in the discovery analysis, 191
SNPs in 72 genes were associated with cortical vBMD and were
genotyped in the validation sample (Fig. 1A). Of these 191 SNPs,
7 SNPs in 5 genes were consistently associated with cortical
vBMD in the validation sample (see Fig. 1B). One SNP was
identified in the IFNAR2 (rs2834160), NFATC1 (rs177820), and
SMAD1 (rs1874572) gene regions, whereas two SNPs were
identified in the HOXA gene cluster (rs6951180 and rs6964896)
and KLF10 gene region (rs3133287 and rs1434278). In addition,
one SNP in IGF1R (rs3784606) and one SNP in TCF4 (rs7240986)
were significant in both the discovery and validation samples,
but the direction of the association was inconsistent.
A pooled analysis was conducted to determine the amount of
variation in cortical vBMD that each of the seven significant SNPs
explained (Table 2). The most significant SNP association was
with rs177820 in the NFATC1 gene region (p¼4 10
 4) that
explained 0.5% of the phenotypic variation in cortical vBMD. For
this SNP, men with the less common GG genotype had 1.2%
lower cortical vBMDthan those with theAA genotype. Additional
adjustment for height and weight did not attenuate the
relationship.
Individual SNPs explained between 0.2% and 0.5% of the
variance in cortical vBMD. Regression models were constructed
to determine the amount of variation explained by all significant
and replicated SNPs. There was high linkage disequilibrium (LD)
between the two SNPs in the HOXA gene region (rs6951180 and
rs6964896, r
2¼0.691, D’¼0.967) and the two SNPs in KLF10
(rs3133287 and rs1434278, r
2¼0.882, D’¼1.000); thus
rs6964896 and rs1434278 were dropped from the regression
modeling to minimize collinearity in the model. The five
remaining SNPs in IFNAR2, NFATC1, SMAD1, HOXA, and KLF10
explained 1.8% of the variance (adjusted r
2) in cortical vBMD
after accounting for age, clinic, population substructure, height,
and weight.
We also identified 255 SNPs in 75 genes that were associated
withtrabecular vBMD(Fig.2A).Weconfirmedanassociationwith
12 of these SNPs in nine genes and trabecular vBMD in the
validation sample (see Fig. 2B). Specifically, associations with one
SNP in ATF2 (rs4972738), BMP7 (rs6127983), FGF18 (rs313543),
FLT1 (rs1408245), TGFB3 (rs7149264), and THRB (rs1505289) and
twoSNPsinAPC(rs459552andrs4705573), BMP3(rs2903746and
rs6814223), and RUNX1 (rs2834676 and rs2834694) were
replicated in the validation sample (see Fig. 2B). In addition,
SNPs in NTRK3 (rs6496469), SOX5 (rs2133345), TCF4 (rs618869),
and TCF7 (rs30496) were significantly associated with trabecular
vBMD in both the discovery and validation samples, but the
direction of association was inconsistent between samples.
Further analysis of the 12 consistently associated SNPs was
conducted in the pooled sample. The most significant SNP
association for trabecular vBMD was with rs2834694 in RUNX1
(p¼5.3 10
 6)that explained 1.0%of the variancein trabecular
vBMD. Individualswith the less common AAgenotype had a14%
higher trabecular vBMD than men with the CC genotype.
Statistical adjustment for height and weight in addition to age,
clinic, and population substructure did not significantly
attenuate the association between the 12 replicated SNPs and
trabecular vBMD (Table 3).
Each of the 12 replicated SNPs individually explained between
0.3% and 1.0% of the variation in trabecular vBMD. None of the
12 replicated SNPs were highly correlated (even those in the
same gene region), and all were entered into a regression model.
After accounting for age, clinic, population substructure, height,
and weight, these 12 SNPs explained 4.0% of the variation in
trabecular vBMD.
Discussion
Studies in humans and animal models suggest that the genetic
determinants of trabecular and cortical BMD may differ, but few
specificlocihavebeenidentifiedforthesebonestrength–related
traits. To our knowledge, the current study is the first to syste-
matically investigate the association between common genetic
variation in candidate genes and vBMD in the trabecular and
cortical bone compartments in humans. We identified several
genetic variants that were associated robustly with cortical or
trabecular vBMD at the femoral neck in a large cohort of older
Caucasian men. Specifically, seven SNPs located in five gene
regions were consistently associated with cortical vBMD and 12
SNPs in nine genes were consistently associated with trabecular
vBMD in two independent samples of men from the same study
Table 1. Characteristics of Older Caucasian Men in the Genotyping Samples
Discovery sample
N¼821
Validation sample
N¼1156
Pooled sample
N¼1977
Age (years) 73 (5.7) 74 (6.0) 74 (5.9)
Height (cm) 173.6 (6.8) 174.9 (6.7)
  174.3 (6.7)
Weight (kg) 85.3 (14.1) 82.9 (12.5)
  83.9 (13.2)
BMI (kg/m
2) 28.3 (4.1) 27.1 (3.6)
  27.6 (3.8)
Femoral neck cortical volumetric BMD (g/cm
3) 0.532 (0.055) 0.520 (0.065)
  0.525 (0.061)
Femoral neck trabecular volumetric BMD (g/cm
3) 0.086 (0.044) 0.062 (0.040)
  0.072 (0.043)
*p<.001.
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ment also was associated with the other compartment. These
results support the hypothesis that some loci for cortical and
trabecular vBMD may be unique for each bone compartment.
To the best of our knowledge, associations of SNPs in IFNAR2,
SMAD1, and KLF10 with BMD have not been described
previously. Evidence specific to cortical bone regulation exists
for one of these novel findings, KLF10. Krupple-like factor 10
(KLF10) is expressed in osteoblasts and is critical for osteoblast-
mediated mineralization and osteoclast differentiation.
(22,23)
KLF10 knockout mice have decreased cortical bone thickness
and osteocyte number.
(24)
We identified a novel association between SNPS in ATF2 and
trabecular vBMD. ATF2 encodes activating transcription factor 2,
a transcription factor that binds to cAMP response elements
(CREs) and stimulates CRE-dependent transcription. The ATF
familyplaysaroleintheexpressionofskeletal-specificgenesand
skeletal development,
(25) including trabecular bone forma-
tion.
(26) Indeed, ATF2 knockout mice lack normal-appearing
trabeculae.
(27) Animal models also show a trabecular phenotype
Fig. 1. SNP association results for femoral neck cortical volumetric bone mineral density. Association results for cortical volumetric bone mineral density
are presented for the first phase of genotyping: (A) discovery sample; (B) validation sample. Specifically, the –log of the p value observed is presented on
the y axis. The most significant result of the two models tested (either additive or recessive) is presented for each SNP. The SNPs are ordered across the x
axis by chromosome and the basepair position on the chromosome. Odd-numbered chromosomes and the X chromosome are presented in gray. Even-
numbered chromosomes are presented in black. In (A), the dark dashed line represents p¼.015 and the dotted line represents p¼.05. In (B), the dotted
line represents p¼.05, and SNPs with p values of .05 or less are labeled with the gene symbol that they lie in.
Table 2. Significant SNP Associations With Cortical Volumetric BMD at the Femoral Neck
Gene SNP Allele Frequency
a
Discovery
sample
Validation
sample Pooled sample
Adjustment 1
b Adjustment 1
b Adjustment 1
b Adjustment 2
c
b P value b P value b P value b P value r
2d
HOXA
e rs6951180 A!G 0.13 0.013 .001
add 0.027 .034
rec 0.025 .017
rec 0.023 .026
rec 0.002
HOXA
e rs6964896 C!A 0.13 0.012 .003
add 0.028 .048
rec 0.025 .025
rec 0.023 .036
rec 0.002
IFNAR2 rs2834160 A!G 0.17 0.011 .002
add 0.022 .025
rec 0.024 .001
rec 0.024 .001
rec 0.005
NFATC1 rs177820 A!G 0.36  0.009 .001
add  0.010 .034
rec  0.013 4 10
 4r e c  0.012 .001
rec 0.005
SMAD1 rs1874572 A!C 0.33 0.017 .003
rec 0.005 .044
add 0.011 .005
rec 0.011 .006
rec 0.004
KLF10 rs1434278 T!A 0.23 0.023 .015
rec 0.006 .037
add 0.006 .002
add 0.006 .001
add 0.005
KLF10 rs3133287 G!C 0.17 0.038 .001
rec 0.006 .055
add 0.007 .001
add 0.007 .001
add 0.005
Note: Additive (add) and recessive (rec) models were tested for each SNP, and the regression parameter and p value from the most significant genetic
model (additive or recessive) are shown.
add¼p value from the additive model; rec¼p value from recessive model.
aMinor allele frequency in the pooled sample.
bAdjustment 1: Age, clinic site, population substructure.
cAdjustment 2: Age, clinic site, population substructure, height, body weight.
dAmount of variation explained after adjusting for age, site, population substructure, height, body weight.
eHOXA genes were tagged as a cluster. They include HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, and HOXA13.
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associated withtrabecular vBMDin this study. BMP3 is one ofthe
most abundant bone morphogenetic proteins (BMPs) in bone
and BMP3 knockout mice have increased trabecular bone.
(28,29)
FLT1 encodes the cell-surface receptor for vascular endothelial
growth factor that is involved in osteoclastogenesis and
osteoblast differentiation.
(30–34) FLT1 null mice have lower
trabecular bone volume.
(35) We also observed an association
between an intronic SNP in the gene encoding thyroid hormone
receptor beta (THRB) and trabecular vBMD. Adult THRB knockout
mice have osteoporosis with reduced trabecular and cortical
bone, reduced mineralization, and increased osteoclast numbers
and activity.
(36)
The two variants in the gene encoding adenomatous
polyposis coli (APC) (rs459552 and rs4705573) were associated
with trabecular vBMD at the femoral neck. APC is involved in
Table 3. Significant SNP Associations With Trabecular Volumetric BMD at the Femoral Neck
Gene SNP Allele Frequency
a
Discovery
sample
Validation
sample Pooled sample
Adjustment 1
b Adjustment 1
b Adjustment 1
b Adjustment 2
c
b P value b P value b P value b P value r
2d
APC rs459552 T!A 0.23 0.006 .018
add 0.004 .049
add 0.004 .005
add 0.004 .006
add 0.004
APC rs4705573 A!G 0.48  0.007 .049
rec  0.007 .012
rec  0.007 .002
rec  0.007 .002
rec 0.005
ATF2 rs4972738 G!A 0.37  0.011 .012
rec  0.007 .054
rec  0.009 .001
rec  0.009 .001
rec 0.005
BMP3 rs2903746 A!T 0.18 0.006 .023
add 0.005 .011
add 0.005 .002
add 0.005 .003
add 0.004
BMP3 rs6814223 G!A 0.13 0.007 .039
add 0.006 .016
add 0.005 .007
add 0.006 .006
add 0.004
BMP7 rs6127983 A!G 0.36  0.009 .053
rec  0.007 .040
rec  0.008 .008
rec  0.007 .007
rec 0.004
FGF18 rs9313543 G!A 0.19  0.017 .029
rec  0.005 .018
add  0.004 .013
add  0.004 .019
add 0.003
FLT1 rs1408245 C!G 0.17  0.026 .008
rec  0.006 .003
add  0.017 .002
rec  0.016 .003
rec 0.004
TGFB3 rs7149264 A!C 0.15 0.006 .034
add 0.004 .050
add 0.005 .008
add 0.005 .011
add 0.003
THRB rs1505289 A!G 0.43  0.004 .048
add  0.004 .034
add  0.004 .003
add  0.004 .003
add 0.004
RUNX1 rs2834676 G!A 0.42 0.005 .030
add 0.010 .003
rec 0.004 .003
add 0.007 .002
rec 0.005
RUNX1 rs2834694 C!A 0.49 0.006 .007
add 0.011 1.4 10
 4r e c 0.010 5.3 10
 6r e c 0.010 4.2 10
 6r e c 0.010
Note: Additive (add) and recessive (rec) models were tested for each SNP, and the regression parameter and p value from the most significant genetic
model (additive or recessive) are shown.
add¼p value from the additive model; rec¼p value from recessive model.
aMinor allele frequency in the pooled sample.
bAdjustment 1: Age, clinic site, population substructure.
cAdjustment 2: Age, clinic site, population substructure, height, body weight.
dAmount of variation explained after adjusting for age, site, population substructure, height, body weight.
Fig. 2. SNP association results for femoral neck trabecular volumetric bone mineral density. Association results for trabecular volumetric bone mineral
densityarepresentedforthediscovery(A)andvalidation(B)samples.Specifically, the–logofthepvalueobservedispresentedon theyaxis,andSNPsare
ordered across the x axis by chromosome and basepair position. The most significant result of the two models tested (either additive or recessive) is
presented for each SNP. Odd-numbered chromosomes and the X chromosome are presented in gray. Even-numbered chromosomes are presented in
black. In (A), the dark dashed line represents p¼.015, and the dotted line represents p¼.05. In (B), the dotted line represents p¼.05, and SNPs with p
values of .05 or less are labeled with the gene symbol that they lie in.
GENETICS OF TRABECULAR AND CORTICAL BMD IN MEN Journal of Bone and Mineral Research 335WNT signaling, is expressed in osteoblasts and osteoclasts, and
osteoblast-specific APC deletion increased bone formation in
mice.
(37–41) The rs459552 variant is of particular interest because
it changes asparagine to a valine residue and is located in the ß-
catenin downregulation domain of APC and may influence WNT
signaling.
(42,43)
The current findings are consistent with an emerging model
whereby some genetic loci for BMD may be specific for cortical
and trabecular bone. For example, genome-wide searches in
inbred mice have identified loci that appear to be distinctly
associated with either cortical or trabecular vBMD
(5,8) Further-
more, family studies have found a low genetic correlation
between trabecular and cortical vBMD, suggesting different
genetic contributions for each bone compartment.
(11) Similarly,
inthe currentinvestigation, none ofthereplicated genesorSNPs
were associated with both cortical and trabecular vBMD at the
femoral neck.
We were able to identify more genetic associations and
explain a greater fraction of phenotypic variation for trabecular
thanfor cortical vBMD. It ispossible that the geneticcontribution
to trabecular vBMD is greater than for cortical vBMD. Indeed,
heritability studies in humans report a lower heritability for
cortical vBMD (17% to 42%) than for trabecular vBMD (59% to
73%).
(9–11) However, the cortical rim of the femoral neck is thin,
and this may have increased measurement error and conse-
quently decreased statistical power at this skeletal region. Future
studies of the appendicular skeleton in regions with a larger
cortical area(e.g., atthe proximaltibia)mayhelptominimize this
issue. Our candidate gene selection also was based on several
informatics resources but may have been unknowingly biased
toward genes influencing trabecular bone. Future studies of
genetic factors for trabecular and cortical vBMD that use
hypothesis-free methods (such as genome-wide investigations)
may yield further insight on the genetic contributions to each
bone compartment.
We were unable to document an association between SNPs in
several widely studied candidate genes or genes identified by
recent genome-wide association studies (e.g., COL1A1, ESR1,
LRP5, VDR, RANKL, TNFRSF11B, and WNT4).
(44–49) There are several
reasons why we may not have been able to replicate these
previous associations. First, our study included only men,
whereas these past studies have focused primarily on women.
Second, most of these prior candidate gene studies measured
integral areal BMD by DXA as opposed to cortical and trabecular
vBMD by QCT. Third, our study was able to detect an SNP
associationthat explainedatleast0.8%ofthe variationinBMD in
the discovery sample with 80% statistical power at alpha¼0.05.
Thus we cannot exclude the possibility of a weaker association
between SNPs in or near these other genes and vBMD at the
femoral neck in older men.
Although the heritability of vBMD is high (estimates range
from 40% to 85%), the amount of phenotypic variation in vBMD
explained by SNPs in the current study was small (1.7% for
cortical vBMD and 4.0% for trabecular vBMD). Although small,
the fractionof variation explainedby these SNPs individually and
collectively is consistent with results from genome-wide
association studies of skeletal-related traits such as BMD and
height.
(48–50) For example, in a recent genome-wide association
study of DXA measures of areal BMD, 0.6% and 0.2% of the
phenotypic variation in lumbar spine and femoral neck BMD was
explained by two SNPs in two genes.
(48) Future studies may need
to consider other types of polymorphisms such as insertion-
deletions, copy-number variants, and less common SNPs (<5%
MAF) as well as interactions between genes and between genes
and environmental factors in order to better account for the
phenotypic variation in vBMD.
Our study has several potential limitations. We focused on
older Caucasian men, and our findings may not be generalizable
to other populations. Additional genotyping in younger men,
ethnically diverse populations, and women will be necessary to
further confirm and extend these SNP association findings.
Although we selected a relatively large number of genes from
bone metabolism pathways in a more comprehensive manner
than most candidate gene studies, future GWAS studies of
cortical and trabecular vBMD may provide additional insights.
Tagging SNP selection was based on phase I of HapMap, which
was the current version when the discovery sample genotyping
was designed. More recent releases would have provided a
denser SNP reference panel from which to select tagging SNPs,
and we ultimately would have achieved a superior genotyping
coverage of HapMap phase II reference SNPs than the 64%
achieved in the current analysis. We also cannot assess the
impact that rare variants might have on trabecular and cortical
vBMD in our study because we restricted our analysis to tagging
SNPs with an MAF  5% and potentially functional SNPs with an
MAF 1%.Finally,itisuncleariftheSNPsidentifiedinthecurrent
analysis have functional consequences or are merely in linkage
disequilibrium with the causal variant(s). Additional studies will
be needed to confirm and refine association signals and to
identify the causal variants involved.
In conclusion, this is the first large-scale investigation of the
potential genetic determinants of cortical and trabecular vBMD
in humans at a clinically relevant skeletal site. The two-stage
internal replication design identified several novel and repro-
ducible genetic associations. Although additional studies are
needed to confirm and extend our findings, the current analysis
suggests that the genetic factors contributing to cortical and
trabecular vBMD among older men may be, at least to some
extent, unique for each bone compartment.
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